Direct oral anticoagulants (doacs) for therapeutic targeting of thrombin, a key mediator of cerebrovascular and neuronal dysfunction in alzheimer’s disease

HIGHLIGHTS

• who: Klaus Grossmann from the Center for Plant Molecular Biology (ZMBP), University of Tu00fcbingen, Tu00fcbingen, Germany have published the paper: Direct Oral Anticoagulants (DOACs) for Therapeutic Targeting of Thrombin, a Key Mediator of Cerebrovascular and Neuronal Dysfunction in Alzheimeru2019s Disease, in the Journal: Biomedicines 2022, 10, 1890. of /2022/
• what: In this study, oral anticoagulant (OAC) use was compared to non-OAC and antiplatelet treatment among AF patients .
• how: This article presents a comprehensive review on latest studies showing that anticoagulants especially of the DOAC-type can be a promising option for a . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.